Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
19 active Medicare policies list M35.9, and 5 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
5 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M35.9 |
|---|---|---|
| Heart-Lung Transplantation | Sep 7, 2023 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Polymerase Chain Reaction Testing: Selected Indications | Feb 9, 2024 | Covered |
| Policy | Effective | Status of M35.9 |
|---|---|---|
| Concert Genetic Testing: Toxicology and Pharmacogenetics Version B | Not recorded | Referenced |
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J9 · Effective Oct 1, 2024
| Pulmonary Function Testing | Not recorded | Covered |
|---|